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Percutaneous coronary intervention (PCI) was introduced
by Gruentzig as an alternative to bypass surgery and was
originally applied for symptomatic patients with single-
vessel disease. As technology advanced, angioplasty became
a therapy for the more usual forms of multivessel disease.
Randomized trials have justified the use of angioplasty in
selected patients with multivessel disease with one glaring
exception—diabetics.
In the six years since the National Heart, Lung and Blood
Institute (NHLBI) issued its clinical alert regarding the
Bypass Angioplasty Revascularization Investigation (BARI)
data, which showed superior five-year survival for coronary
artery bypass graft (CABG) compared to angioplasty (1),
interventional cardiologists have been hoping for a “re-
count.” Was there something unique about the population?
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Did the findings apply to only a subset of patients with
diabetes? Most have accepted the BARI findings and some
have modified their approach to patients with diabetes.
However, physicians continue to look for explanations for
the difference, for other experiences that could clarify which
patients are at greatest risk for angioplasty and reassurance
that new technology has improved the outcomes for patients
having interventions.
The report in this issue of the Journal describes a carefully
collected experience among patients with diabetes undergo-
ing revascularization in the mid-1990s (2). This study from
the Northern New England group is important because,
unlike a randomized trial or a large single-center experience,
it captures the practice of an entire, albeit small, region.
Prospective data collection identified the population by
certain demographic, clinical and angiographic characteris-
tics. Although not as detailed as would be found in a
prospective randomized trial, this method is far superior to
retrospective data collection methods. The practice of re-
vascularization therapy reflects the standard of care deliv-
ered during the time of the study, and follow-up vital status
was obtained from the National Death Registry.
Among 7,159 patients with diabetes undergoing PCI in
the years 1992 to 1996, some 2,766 were similar in baseline
features to patients in the BARI trial and registry. That is,
they had multivessel disease and lacked the BARI exclu-
sions. Selection for revascularization by the physician caring
for the patients resulted in 736 patients undergoing initial
PCI and 2,030 having initial surgery. After adjustment for
baseline characteristics, the PCI patients had a 1.5-times
greater risk of dying than the patients having initial bypass
surgery (hazard ratio [HR] 1.49, p 5 0.037). The BARI
hazard ratio was 1.78 favoring surgery (3).
A search for other experiences has not produced impor-
tant changes in the vote count favoring surgery. The largest
reported single-center registry of patients with diabetes was
from Emory University and confirmed a high mortality for
diabetics treated with surgery or angioplasty (4). The
surgery group of diabetics on insulin had a significantly
better adjusted survival rate than the PCI group. Long-term
follow-up of the Emory Angioplasty vs. Surgery Trial
(EAST) also showed a trend favoring surgery in the patients
with diabetes similar to BARI (5). Eight-year survival was
75.5% in the CABG group and 60.1% in the percutaneous
transluminal coronary angioplasty (PTCA) group. This
compares to seven-year survival of 76.4% and 55.7% for
BARI (6). As the investigators (2) of the current study point
out, other registries and randomized trials also trend toward
better survival with surgery.
Three important questions are raised by the prior expe-
riences and the current observation: 1) What are the
explanations for surgical superiority? 2) Will new develop-
ments significantly improve the long-term survival for
patients treated with PCIs? 3) Is bypass surgery protective in
patients with diabetes?
WHY HAS SURGERY BEEN SUPERIOR?
Examination of surgical curves from the BARI and EAST
studies and from the current registry showed that the
difference in long-term survival was not driven by operative
mortality but by late events. Incomplete revascularization,
restenosis and progression of disease may all be responsible.
The EAST trial included follow-up angiography at one and
three years. Although most surgical patients had complete
revascularization, the number of narrowed segments that
were open in the angioplasty group proved significantly less.
At one year, the percent of revascularized segments in the
angioplasty group was 59% versus 88% for surgery and by
three years 70% versus 87% due to repeat revascularization
in the angioplasty group (7). Systematic follow-up angiog-
raphy was not performed in other studies, but a similar
superiority for surgical revascularization would be expected.
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In the present study, the surgery group had 3.8 distal
anastomoses placed per patient, whereas 74% of the PCI
patients had some vessel with significant obstruction not
treated. One assumes that these were the less critical vessels,
but it is evident that surgery produces more complete
revascularization in most of these patients.
The increased restenosis rate in patients with diabetes
also adds to the surgical advantage in the first year postin-
tervention. The survival curves in this study are less steep
than previous randomized trials, suggesting careful patient
selection for PCI patients. Nonetheless, the continuing late
events suggest that progression of disease is a very important
determinant of survival. Current recommendations for op-
timal glycemic control, blood pressure and lipid manage-
ment may not have been optimally understood or practiced
during the observation period of this as well as prior studies.
WILL NEW DEVELOPMENTS IMPROVE
SURVIVAL FOR DIABETICS UNDERGOING PCI?
Stenting, performed in only 14% of this group, has been
shown to reduce emergency surgery and restenosis rates.
Despite this fact, stenting in patients with diabetes still
carries a higher restenosis and reintervention risk than in
nondiabetic patients. A registry from the Washington
Hospital Center of 954 stented patients with diabetes
showed that freedom from late events of death, myocardial
infarction (MI) or revascularization was 60% in the insulin-
treated patients, 70% in the non-insulin-treated diabetics,
and 74% in the nondiabetic patients (8). Another study of
stented patients with diabetes from Hamburg shed some
light on why this occurs. Quantitative angiography showed
that insulin-treated diabetics had smaller vessels (2.73 mm
vs. 2.88 for nondiabetics) and had more in-stent prolifera-
tive tissue at follow-up, resulting in restenosis rates of 39.6%
for insulin-treated, 32.8% for non-insulin-treated diabetics
and 23.8% for nondiabetics (9). This smaller arterial size in
diabetics has also been observed recently by Steve Nissen
(personal communication) using intravascular ultrasound.
Emergency surgery rates have been reduced to ,2% ever
since stenting became a common practice. The 1999
NHLBI Dynamic Registry patients who had BARI char-
acteristics were compared to the BARI randomized pa-
tients. Stenting was not used in BARI but was used in 86%
of the recent registry patients. Emergency surgery following
a PCI was reduced from 10.2% to 1.8% in the recent registry
group (Detre KM, University of Pittsburgh Core Data
Center).
Will survival be impacted by the use of stents? Diabetic
patients treated in New York State between 1994 and 1996
had a better adjusted two-year survival following stent
placement than following balloon angioplasty (HR 5 1.46)
(10). The only reported trials of surgery versus PCI using
stents is the Artery Revascularization Therapy Study
(ARTS). One-year results show that the reintervention rate
has been reduced by approximately 50% compared to prior
CABG versus balloon angioplasty trials (Serruys PW, per-
sonal communication, December 2000). The mortality for
diabetic patients at one year is 3.1% for the surgery group
and 6.4% for the stent group. This difference does not reach
significance, and based on previous trials much longer
follow-up is needed. Another revascularization trial using
stents, termed Stent or Surgery (SOS), is to be reported in
March 2001.
Antiplatelet therapy with glycoprotein IIb/IIIa receptor
blockers has reduced periprocedural MI. Data from the
EPISTENT (11) trial shows a lower in-stent restenosis rate
and slightly improved survival for patients with diabetes
treated with stents and abciximab. Additional information
from the recently completed TARGET trial of tirofiban and
abciximab will give additional insights into the value of
these agents in preventing late events in patients with
diabetes. The 30-day outcome showed no increase in early
events of stented diabetic patients compared to stented
nondiabetic patients treated with either glycoprotein IIb/
IIIa receptor blocker (presented at American Heart Asso-
ciation meeting, November 2000).
Recent advances in medical therapy of diabetic patients
may modify the late-event rate for patients undergoing both
PCI and surgery. The UK Prospective Diabetes Study
(UKPDS) showed a reduction in microvascular complica-
tions and suggested a benefit in reducing heart attacks by
tighter glycemic control (12). The Heart Outcomes Preven-
tion Evaluation (HOPE) trial (13) showed a reduction in
ischemic events in the diabetics treated with angiotensin-
converting enzyme (ACE) inhibitors. Guidelines based on
the Scandinavian Simvastatin Survival Study (4S) trial (14)
and other secondary prevention trials have resulted in lower
targets for low density lipoprotein (LDL) cholesterol in
diabetics. Angiographic progression in the EAST trial was
found to be associated with LDL levels, the cholesterol to
high density lipoprotein (HDL) ratio and recently with the
small, dense LDL pattern suggesting further therapeutic
options for these patients (15).
IS BYPASS SURGERY PROTECTIVE?
In the current study, the surgery group may have benefited
from the frequent use of the internal mammary artery graft.
This conduit is commonly used to bypass the left anterior
descending (LAD) coronary artery and has been shown to
have superior long-term patency compared to saphenous
vein grafts. An interesting observation is that 81% of the
diabetic patients in BARI received internal mammary artery
grafts. It is also worth noting that the survival benefit seen
in the diabetic group was driven by a difference in cardiac
survival (cardiac mortality at five years was 5.8% for surgery
and 20.6% for PTCA). How did the use of the internal
mammary artery graft influence the outcomes? Obviously
there were anatomic factors driving the use of the internal
mammary artery, but the seven-year survival for surgery
patients with an internal mammary artery was 83.2%; for
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surgery patients with saphenous vein grafts it was only
54.5%; and for PTCA patients it was 55.5%. Nondiabetic
patients had approximately 86% survival at five years in all
three groups.
How could the use of the internal mammary artery graft
protect the patient with diabetes? It is possible that a graft
with excellent longevity placed distal in the most critical
artery (the LAD) could remain viable even if coronary
events (plaque rupture) occurred in the proximal and mid-
segments of the vessel due to disease progression over many
years of follow-up. A proximally performed balloon angio-
plasty or stent placement could not solve the problem of
more distal plaque rupture.
One other bit of evidence from the BARI study may be
instructive. All BARI randomized and registry patients were
separated into those who received surgery at any time and
those who remained surgery free. Spontaneous Q-wave MI
occurred in 8% of the diabetic patients during follow-up.
The mortality risk following an MI was 10 times greater for
those diabetics who had not undergone prior surgery com-
pared to those who had (HR for surgery patients 0.09) (16).
This did not hold for the nondiabetic patients. Could the
use of the internal mammary artery (91%) in the current
study have protected the surgery group from a fatal MI?
There is not sufficient data to be sure.
HOW SHOULD THE FINDINGS OF THIS STUDY
AND THE OTHERS HELP INFLUENCE PRACTICE?
Overall, the vote is in and the winner has been declared.
Surgery with at least one internal mammary artery graft is
superior to angioplasty in the broad population of patients
with diabetes and multivessel disease. All patients, however,
do not fit the mean. In this study, the patients with two-vessel
disease did not have a significantly worse outcome with PCI.
There are probably some two-vessel patients who will do
equally as well and some who will not. That discrimination is
beyond the capability of this registry as it would require a
careful angiographic core laboratory evaluation.
Because PCI has undergone significant changes and is
still widely applied in diabetic patients, it would be helpful
to follow the investigators’ advice and perform future
registries. The NHLBI Dynamic Registry is such an effort,
and others limited to patients with diabetes may also be
instructive. The pending BARI 2-D study, which will
evaluate revascularization versus medical therapy in patients
with diabetes, will follow guidelines based on the previously
developed evidence from trials and registries.
In the meantime, the present study provides supporting
evidence that the most prudent selection for PCI in diabetic
patients with multivessel disease will be those patients who
require interventions and have favorable features, such as
predominantly two-vessel disease, absence of proximal
LAD disease, discrete lesions favoring PCI therapy, and
those patients with a reasonable opportunity to provide
nearly complete functional revascularization. Vigorous sec-
ondary prevention must be provided. The accepted treat-
ment guidelines being applied in the BARI 2-D trial (i.e.,
tight glycemic control, LDL cholesterol ,100 mg/dl, and
blood pressure ,135/85 mm Hg) should be the goals. In
addition, heightened surveillance of all diabetic patients who
have had PCI should be practiced. Finally, a recount will be
required as new technology and medical therapies emerge.
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